Complete testicular feminization caused by an amino-terminal truncation of the androgen receptor with downstream initiation.

S. Zoppi, Carol M. Wilson, Madeleine D. Harbison, Jim E. Griffin, J D Wilson, Michael J. McPhaul, Marco MarcelliJournal of Clinical Investigation 1993 · DOI

Abstract

This study characterizes the molecular defect causing androgen resistance in two 46,XY siblings with complete testicular feminization. While hormone binding studies in genital skin fibroblasts showed residual activity, no immunoreactive androgen receptor (AR) was detected using anti-NH2-terminal antibodies, suggesting an abnormal amino terminus. Genetic analysis revealed a point mutation (CAG $\rightarrow$ TAG, Gln60 $\rightarrow$ Stop) at nucleotide 340. In vitro studies demonstrate that AR synthesis is re-initiated downstream of this stop codon, resulting in a truncated protein produced at low levels with significantly impaired function. This novel mechanism highlights the vital role of the amino-terminus in AR function and enabled successful prenatal diagnosis in the affected family.

Introduction

Androgen Insensitivity Syndrome (AIS), or testicular feminization, occurs when individuals with a 46,XY genotype are resistant to male sex hormones, resulting in a female physical phenotype. While many cases are linked to mutations in the hormone-binding or DNA-binding domains, the role of the amino-terminus—the front end of the protein—has been less clearly defined. This research investigates two siblings with complete androgen resistance to understand how a mutation in this specific region completely disrupts receptor function, even when the hormone-binding domain remains largely intact.

Methods

The research team employed a multi-faceted approach to identify the molecular basis of the disorder:

  • Fibroblast Binding Studies: Cultured skin cells from patients were used to measure the binding capacity ($B_{max}$) and dissociation rates of dihydrotestosterone (DHT).
  • Genetic Sequencing: The AR gene was amplified and sequenced to identify the specific mutation.
  • Functional Expression: Site-directed mutagenesis recreated the mutation in vitro. These mutant genes were expressed in various cell lines (CHO, CV1, and COS) to observe protein production and transcriptional activation of reporter genes.
  • Immunoblotting: Specific antibodies were used to determine the size and quantity of the resulting receptor proteins.

Key Insights: Downstream Initiation and Functional Impairment

The identified mutation (Q60X) changes a glutamine codon into a "Stop" signal early in the gene. Typically, such a mutation prevents the production of any functional protein. However, the study found that the cell's translation machinery "re-initiated" synthesis at a downstream site, specifically at Methionine 188.

Figure 1: (A) Pedigree of the family showing the inheritance of the abnormal allele. (B) Schematic of the human AR showing the position of the mutation detected in subjects R776 and R782.

This "downstream initiation" produced a truncated 87-kD protein, compared to the normal 110-kD receptor. This mechanism causes androgen resistance through a "double whammy":

  1. Reduced Quantity: Downstream initiation is highly inefficient, leading to approximately 100-fold lower levels of the receptor protein.
  2. Reduced Quality: The truncated molecules are functionally impaired, possessing only a fraction of the normal transcriptional activity. At equivalent expression levels, the mutant showed only ~8% of normal activity.

Results and Clinical Application

In cell assays, the mutant receptor required much higher concentrations of DNA to produce even a weak signal. Even when "overexpressed" in the laboratory, its activity reached only ~30% of the normal maximum.

Crucially, identifying this mutation allowed the team to perform a successful prenatal diagnosis for a third sibling. They confirmed that the 46,XY fetus did not carry the mutation at 9 weeks gestation, providing vital information for the family's clinical management.

Conclusion

These results define a novel mechanism for androgen resistance: the combination of decreased protein amount and functional impairment caused by an abnormality within the amino terminus of the receptor. The findings suggest that domains critical for the in vivo function of the receptor reside within the amino terminus, and their disruption can lead to complete resistance even with relatively subtle effects on hormone binding.

Summary updated

Abstract

We have characterized the molecular defect causing androgen resistance in two 46,XY siblings with complete testicular feminization. Although binding studies in genital skin fibroblasts showed a reduced Bmax, an increased dissociation rate of ligand, and an 8S peak of dihydrotestosterone binding on sucrose density gradient centrifugation, no immunoreactive androgen receptor (AR) was detected in immunoblots using anti-NH2-terminal antibodies, suggesting an abnormal amino terminus. Sequence analysis of the AR gene revealed a point mutation CAG-->TAG (Gln-->Stop) at nucleotide 340. In vitro mutagenesis studies suggest the synthesis of the mutant AR is initiated downstream of the termination codon at reduced levels and that each molecule is functionally impaired. These results define a novel mechanism causing androgen resistance: the combination of decreased amount and functional impairment of AR caused by an abnormality within the amino terminus of the receptor. These findings suggest that domains important to the in vivo function of the receptor reside within the amino terminus and that disruption of these domains can occur with only subtle effects on receptor binding. Identification of this mutation made it possible to identify the mutant allele within the family and to ascertain antenatally that it was not present in a 46,XY fetal sibling of the proband at 9 wk gestation.
BibTeX
@article{zoppi1993complete,
  author = {S. Zoppi and Carol M. Wilson and Madeleine D. Harbison and Jim E. Griffin and J D Wilson and Michael J. McPhaul and Marco Marcelli},
  title = {{Complete testicular feminization caused by an amino-terminal truncation of the androgen receptor with downstream initiation.}},
  journal = {Journal of Clinical Investigation},
  year = {1993},
  doi = {10.1172/jci116269},
}
Figure